Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
about
The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in ChinaImmunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatmentUpdate on treatment of light chain amyloidosisA rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operativEfficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trialA phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.Light-chain amyloidosis: SCT, novel agents and beyond.Light chain amyloidosis 2012: a new era.Immunoglobulin light chain amyloidosis.Future directions in the clinical management of amyloid light-chain amyloidosis.The ecology of cancer from an evolutionary game theory perspective.Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Pathophysiology and treatment of cardiac amyloidosis.Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.Attitudes about when and how to treat patients with AL amyloidosis: an international survey.Recent advances in the management of AL Amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.Novel pharmacotherapies for cardiac amyloidosis.New and developing therapies for AL amyloidosis.Disease burden of systemic light-chain amyloidosis: a systematic literature review.Newer Therapies for Amyloid Cardiomyopathy.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives.New concepts in the treatment and diagnosis of amyloidosis.Light Chain Amyloidosis.Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosisNovel Therapies in Light Chain Amyloidosis.Recent advances in understanding and treating immunoglobulin light chain amyloidosis
P2860
Q26740439-786F4072-59A3-4EE9-918A-76F29108A231Q26827340-4735EDFF-793A-4C18-BC25-73B13BCEB2CFQ26829735-8F16D978-A57E-4F25-9FF8-41BAE32EFE73Q33802749-4F8A9196-591B-4388-9A09-21A2A16052ADQ34448455-AD62DD08-08B1-4805-ABBD-7128BE58F458Q35571048-6D376362-03A3-4116-840B-3C553E01D933Q36036322-04C7C0B4-5AE7-4B0F-8A63-5008C0E9A198Q36805878-8B0331DF-68EC-4782-A69F-8501C4A81035Q36862339-8C1C28C8-42A0-4644-B353-C40FEF3E9B21Q37212712-FFA54667-79DA-4CC3-AF5A-4A5D61DE3DA7Q37676296-F2C091B2-F1B9-497F-BC0D-D1ABD0AFD513Q38056010-0A1C17B3-9161-414F-91C3-3755BC60802CQ38072108-1E04F105-C07B-4A96-936E-8FCE494B1186Q38172295-A1A4917D-745B-49FF-8016-73BD0C4659A0Q38172998-ED3ED6E0-BADB-4994-BC2B-4B8ED0FE6C69Q38237394-F0F9014F-0A7D-428B-B951-4E243E66C9A0Q38244397-8980C6D6-7BFA-404A-9633-796DA3FD42E5Q38259728-AC686BD4-CFD7-4B90-BA52-6A1F3B67FE59Q38376616-74709F75-0472-479A-8003-774EC56733FBQ38411566-EE9A7640-DA26-4D74-8FFC-1365B95862C9Q38600436-B8913B38-F423-4D23-A857-9FBF87AEC369Q38613822-B99DE902-619A-4A97-8CED-43AC5F8CA4F2Q38614967-BF3C8989-D68F-4AA2-8451-F05B78DBDE4AQ38709793-50901B6D-3386-4273-BA6C-25CEDBA1DD96Q38779623-82DA2BDA-DB7B-49AF-94A1-0483D9CED789Q38917828-91977254-2913-4EAB-B276-5D8DA94A19CAQ38920614-904B7C49-FFC1-4245-AE3F-27C4968701DCQ38928383-642A2740-97E7-4836-8511-4223A3395A20Q41080053-934FAA7A-4EDB-4FF5-BADF-81281EE092B9Q41593651-E3DFBB22-DA67-4DDB-A9F7-269C85753EF8Q41645533-00517F88-BD47-45FD-ADDA-DAB329110BA7Q43057972-B8104F64-1B6C-4373-8F98-48D59BCCE7DAQ43181388-0E254A95-2D4B-4AEF-8340-E39602A122C4Q47561519-1C3980CF-3346-4287-89A4-3CE500CB6BBBQ52659305-622449BA-9430-48FC-99AB-E716076CDB7EQ52716575-97A4F6ED-E4AB-4201-8E88-C70B4E1A5CF7Q55127439-D3686A3A-CE74-4CE4-BB41-ADF5501E1929Q57166910-22C82D99-DC72-4EC9-8950-847173D58739
P2860
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Lenalidomide, cyclophosphamide ...... results from a phase 2 trial.
@ast
Lenalidomide, cyclophosphamide ...... results from a phase 2 trial.
@en
type
label
Lenalidomide, cyclophosphamide ...... results from a phase 2 trial.
@ast
Lenalidomide, cyclophosphamide ...... results from a phase 2 trial.
@en
prefLabel
Lenalidomide, cyclophosphamide ...... results from a phase 2 trial.
@ast
Lenalidomide, cyclophosphamide ...... results from a phase 2 trial.
@en
P2093
P2860
P50
P1433
P1476
Lenalidomide, cyclophosphamide ...... results from a phase 2 trial.
@en
P2093
A Keith Stewart
Craig B Reeder
Francis K Buadi
Jacob Allred
John A Lust
Joseph R Mikhael
Kristina M Laumann
Leif P Bergsagel
Philip R Greipp
Rafael Fonseca
P2860
P304
P356
10.1182/BLOOD-2012-01-407791
P407
P50
P577
2012-04-13T00:00:00Z